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SUMMARY 
 
Typical and atypical antipsychotics can be characterized at preclinical levels by 
differential induction of several Immediate Early Genes localized at cortical and 
subcortical regions related to pathogenesis of  psychiatric disorders and antipsychotics 
action. So, genes expression. Molecular imaging under different treatment paradigms 
could be considered a sensitive molecular tool to investigate where drugs act, 
predicting, with a translational approach a clinical outcome. In clinical practice 
psychiatrists frequently switch from one antipsychotic to another with different 
receptorial profile when patients show poor or no treatment response or intolerable 
adverse effect, but the post-switch antipsychotics response is different compared to drug 
naïve patients. Neuroimaging studies highlighted morphological and molecular changes 
after long-term administration in brain regions affected by antipsychotics, resulting in 
unexpected clinical outcome. In our study we analyze Immediate Early Genes 
expression of proteins localized ad Postsynaptic Density (PSD), where dopaminergic 
and glutamatergic transmission converging, in an animal model of switching. Thus we 
highlight that first chronic treatment with strong D2 blocker affects genes expression 
induced by second chronic treatment with antipsychotic characterized by a different 
receptorial profile, confirming, at molecular level, what happens in clinical practice and 
giving new challenges towards antipsychotic mechanism of action.   
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BACKGROUND 
Antipsychotics represent the cornerstone of schizophrenia pharmacological treatment. 
The efficacy of each antipsychotics is different among schizophrenic patients, but 
approximately 10%-30% of patients show little or no response or intolerable adverse 
effects, so necessitating a change in their medication regimen (Lieberman et al., 2005;  
Elkis and Meltzer, 2007). 
Switching from one antipsychotic to another when facing poor response is common 
clinical practice, but it could be a potentially destabilizing event because it could lead to 
rebound and withdrawal phenomena (Correll, 2010; Correll, 2011).  
Rebound effects involve exposure of previously blocked receptors to the endogenous 
ligand or to the different receptor profile of the post-switch antipsychotic (Correll, 
2010). Several evidence have established that chronic antipsychotic administration 
causes biological adaptation to counteract the postsynaptic dopamine D2 receptor 
blockade. SPECT studies show an increased number of DAT binding sites in the 
schizophrenic patients treated with D2 receptor blocking neuroleptics (Sjoholm et al., 
2004). Furthermore preclinical  evidence have shown recently that  antipsychotics  may 
affect directly brain structure determining morphological changes after long-term 
administration (Vernon et al., 2011). 
MRI studies in schizophrenic patients, even if are not always consistent, show 
morphological changes induced by chronic antipsychotic administration in caudate, 
putamen and globus pallidus, regions related with schizophrenia symptoms, 
antipsychotic efficacy and motor side effect  (Corson et al., 1999); switch to atypical 
antipsychotic as olanzapine or clozapine reverses the anatomical modification following  
typical antipsychotic long-term treatment (Scheepers et al., 2001; Lang et al., 2004). 
Indeed chronic antipsychotic administration causes changes across the synapse resulting 
in unexpected clinical outcome of patients after switching from one antipsychotic to 
another with different D2 affinity (Buckley et al., 2007), but studies in animal model are 
lacking. 
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Despite being a common clinical practice, switching antipsychotics has been 
surprisingly studied very little in preclinical paradigm, specifically with regard to the 
effects on brain activation and gene expression induction, leaving some question 
unexplored. 
Mapping temporal and spatial  changes in  gene expression is a powerful tool for 
studying where antipsychotics switching. The Postsynaptic Density (PSD) is a 
specialized structure of postsynaptic membrane of glutamatergic synapses, where 
glutamatergic and dopaminergic system interact and which mediate transductional 
signalling and synaptic plasticity (Sheng et al., 2007). 
To test changes in gene expression, among other components of PSD, we focus on 
Homer, a family of scaffold proteins localized at PSD, including both constitutive 
(Homer 1b/c, Homer 2 a/b, Homer 3) and inducible (Homer 1a and ania3) isoforms, 
which have a key role in regulating the synaptic architecture (Fagni et al., 2002; 
Hayashi et al., 2009) and the molecular rearrangement of PSD after challenging 
dopaminergic neurotransmission (Iasevoli et al., 2009). Moreover Homer 1-KO mice 
exhibit behavioural and neurochemical abnormalities that are consistent with the animal 
models of schizophrenia and  the regulation of extracellular levels of glutamate within 
limbo-cortico-striatal structures by Homer 1 may be involved in the pathogenesis of 
schizophrenia (Szumlinski et al., 2005). 
Homer constitutive isoform interact with other PSD proteins included glutamate 
receptors, kinases and cytoskeleton proteins so exerting a structural role in dendritic 
spines architecture, regulating trafficking and redistribution of metabotropic glutamate 
receptor (mGluRs), crosstalking between NMDARs and mGluRs  and bridging of 
inositol 1,4,5-triphosphate receptors (IP3Rs) to mGluRs, providing a link between 
glutamate receptors and intracellular signal transduction system (de Bartolomeis et al., 
2003). Homer 1a induction disrupts the cluster of proteins formed by constitutive 
isoforms leading to a changes in postsynaptic density morphology. Several stimuli have 
been demostrated to induce Homer 1a expression, including antipsychotic 
administration. Homer-regulated PSD remodelling may represent a mechanism of 
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synaptic plasticity, and it could be involved in molecular changes associated to 
pharmacotherapy (Tomasetti et al., 2007). It has been shown that haloperidol, a strongly 
D2 blocker, robustly induce the expression of Homer1a in all subregions of the caudate-
putamen, whereas atypical antipsychotics, having a lesser D2 blockade rate, does not 
(Iasevoli et al., 2010; Iasevoli et al., 2010; Iasevoli et al., 2011). 
Moreover, differently from other immediate early genes, expression of which is 
modulated by antipsychotics (i.e., cfos, arc) (Fumagalli et al., 2009), the up-regulation 
of Homer1a induced by acute antipsychotics administration hold steady in chronic 
paradigms (Ambesi-Impiombato et al., 2007; Tomasetti et al., 2011). From a clinical 
point of view, the lack of sensitization of Homer1a after long-term treatment makes it a 
good candidate as molecular marker of treatment response. 
Arc is a PSD protein involved in rapid cytoskeletal rearrangements in response to 
several synaptic stimuli (Bramham et al., 2008), and its gene expression may mark fast 
structural changes in the PSD. Moreover, Arc expression has been found affected by 
antipsychotics (de Bartolomeis et al., 2013; Iasevoli et al., 2010; Fumagalli et al., 2009; 
Luoni et al., 2014). Psd-95 is a scaffolding protein, whose functions include the control 
of glutamatergic, dopaminergic, and serotonergic receptors trafficking throughout the 
PSD and positioning onto membrane surface (Iasevoli et al., 2013), thereby deeply 
influencing receptor signaling and PSD plasticity. All together these molecules are 
considered relevant for dendritic architecture and related functional changes as well as 
for synaptic plasticity disorders in neurobehavioral diseases (Kirov et al., 2012; Cohen 
et al., 2011).   
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AIM OF THE STUDY 
The aim of the study is to investigate the effect on gene expression of chronic treatment 
with an atypical antipsychotic, after prolonged chronic treatment with a strong D2 
blocker, such as haloperidol, in order to analyze, at molecular level, a clinical practice 
of switching. We focus on Immediate Early Genes Homer1a and Arc and constitutive 
genes Homer1b and Psd-95, localized at PSD level, which likely could be involved in 
molecular changes related to antipsychotic response.  
“Switching” is a change in medication regimen from a chronic treatment with an 
antipsychotic to a chronic administration with another antipsychotic characterized by a 
different receptorial profile. Clinical evidence showing an unexpected outcome in 
schizophrenic patients long lasting treated when switch antipsychotic, compared to 
patient drug-naive. Indeed several neuroimaging studies demonstrated a morphological 
changes induced by chronic antipsychotic administration in caudate, putamen and 
globus pallidus, regions related to schizophrenic symptoms, antipsychotic efficacy and 
motor side effect  (Corson et al., 1999). Neverthless, molecular finding that investigate 
in a preclinical paradigm switching are lacking.  
We have choosen amisulpride as post-switch antipsychotic because, despite its high 
affinity to D2 receptor, comparable to haloperidol, it has the clinical profile of atypical 
antipsychotics (eg a low potential to cause extrapyramidal symptoms (EPS)) (La 
Fougere et al., 2005). 
However unlike other atypical antipsychotic which bind to multiple receptors, 
amisulpride is devoid of any significant affinity to other receptors (Schoemaker et al., 
1997). Indeed, its activity at presynaptic D2/D3 receptors is responsible for enhancing 
dopamine transmission (Moller et al., 2003; Lecrubier et al., 2000). 
Then for its unique receptorial profile, amisulpride allows to better understand 
molecular changes and then the downstream effects after manipulating dopaminergic 
neurotransmission system in subcortical regions involved in pathogenesis of 
schizophrenia, antipsychotic treatment response and motor side effects. 
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MATHERIALS AND METHODS 
Acute paradigm. 
In the acute paradigm male Sprague-Dawley rats were randomly assigned to one of the 
following experimental treatment group: vehicle (VEH); haloperidol 0.8 mg/kg (HAL); 
amisulpride 10 mg/kg (AMS10); Amisulpride 35 mg/kg (AMS35) and received a 
unique administration. Animals were injected intraperitoneally (i.p.), mildly 
anaesthetized by chloral hydrate, and killed 90 min after administration. We had 
choosen two different doses to mimic clinical practice, where amisulpride is effective at 
low dose on dystimia and negative symptoms of schizophrenia (Boyer et al., 1995), at 
high dose on positive symptoms (Lecrubier et al., 2000; Moller et al., 2003). On the 
molecular point of view, low dose believed to block preferentially presynaptic 
dopamine autoreceptors, thereby regulating dopamine release (Schoemaker et al., 
1997); high dose predicted to block both pre- and postsynaptic dopamine D2 receptors 
(Perrault et al., 1997).  
 
Switching paradigm. 
Experimental paradigm resembling, with a translational approach, a common clinical 
practice of switching was designed. Initially rats were randomly assigned to one of the 
following treatment groups (n=18 animals for each treatment group): vehicle (veh) or  
haloperidol 0.8 mg/kg (hal) and received daily treatments for 15 days; from on day 
sixteen rats of each group  were switched to vehicle, haloperidol or amisulpride and 
received daily treatment for 15 days more; so they were randomly assigned to the 
following treatment groups (n=6 animals for each treatment group, pretreament 
condition/switch condition): vehicle (veh/veh); haloperidol 0.8 mg/kg (veh/hal); 
amisulpride 35 mg/kg (veh/ams), which had receiving first vehicle treatment and 
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vehicle (hal/veh), haloperidol (hal/hal) and amisulpride (hal/ams), which had receiving 
first haloperidol treatment. We have used amisulpride at 35mg/kg dose because at this 
dosage it has been shown to block pre- and postsynaptic dopamine D2 receptor (Perrault 
et al, 1997) and to induce a peculiar striatal pattern of Immediate Early Gene expression 
(de Bartolomeis et al., 2013). 
 
 
 
 
 
 
 
PICTURE 1. Experimental design (above). Regions of Interest (below). 
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Animals 
Male Sprague-Dawley rats (mean weight 250g) were obtained from Charles-River Labs. 
(Lecco, Italy). The animals were housed and let to adapt to human handling in a 
temperature and humidity controlled colony room with 12/12 h light–dark cycle (lights 
on from 6:00 a.m. to 6:00 p.m.) with ad libitum access to laboratory chow and water. 
All procedures were conducted in accordance with the NIH Guide for Care and Use of 
Laboratory Animals (NIH Publication No. 85-23, revised 1996) and were approved by 
local Animal Care and Use Committee. All efforts were made to minimize animal 
number and suffering. 
Amisulpiride powder (Sanofi-Aventis, Italy) and Haloperidol injectable solution 
(Lusofarmaco, Italy) were dissolved in saline solution (NaCl 0.9%). All solutions were 
adjusted to physiological pH value and injected i.p. at a final volume of 1 ml/kg. 
Animals were injected intraperitoneally (i.p.), and sacrificed by decapitation 90 minutes 
after the last administration. 
 
In Situ Hybridization. 
After sacrifice, the brains were rapidly removed, quickly frozen on powdered dry ice 
and stored at -70°C prior to sectioning. Serial coronal sections of 12 μm were cut on a 
cryostat at -18°C through the forebrain at the level of the middle-rostral striatum 
(approx. from Bregma 1.20mm to 1.00mm), using the rat brain atlas by Paxinos and 
Watson (Paxinos and Watson 1997) as an anatomical reference. Care was taken to 
select identical anatomical levels of treated and control sections. Sections were thaw-
mounted onto gelatin-coated slides, and stored at -50ºC for subsequent analysis. 
Homer 1a, Arc, PSD-95 and Homer1b/c probes were oligodeoxyribonucleotides derived 
from identical probes used in previous hybridization studies (Ambesi -Impiombato et 
al., 2007;  Tomasetti et al., 2007; Iasevoli et al. 2010;  de Bartolomeis et a., 2011, 
2013). All the oligodeoxyribonucleotides were purchased from MWG Biotech (Firenze, 
Italy). 
For each probe a 50μl labeling reaction mix was prepared on ice using DEPC treated 
water, 1X tailing buffer, 7.5pmol/μl of oligo, 125 Units of TdT and 100mCi 35S-dATP. 
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The mix was incubated 20 min at 37°C. The unincorporated nucleotides were separated 
from radiolabeled DNA using ProbeQuant G-50 Micro Columns (Amersham-GE 
Healthcare Biosciences; Milano, Italy). As an assessment of the probe specificity, the 
autoradiographic signal distribution was compared and found to be consistent  for 
topography and with previous in situ hybridization studies (Brakeman et al., 1997; 
Polese et al., 2002). The specificity of each oligonucleotide probe was also tested by 
pilot control experiment using the corresponding sense oligodeoxyribonucleotide. 
Sections were processed for radioactive in situ hybridization according to previously 
published protocols (Ambesi-Impiombato et al., 2003; Iasevoli et al 2012, de 
Bartolomeis et al 2013). All solutions were prepared with sterile double-distilled water. 
The sections were fixed in 4% formaldehyde in 0.12 M phosphate buffered saline (PBS, 
pH 7.4), quickly rinsed three times with 1X PBS, and placed in 0.25% acetic anhydride 
in 0.1 M triethanolamine/0.9% NaCl, pH 8.0, for 10 minutes. Next, the sections were 
dehydrated in 70%, 80%, 95% and 100% ethanol, delipidated in chloroform for 5 
minutes, rinsed again in 100% and 95% ethanol and air dried. 
Sections were hybridized with 0.4-0.6x10
6
 cpm of radiolabeled oligonucleotide in 
buffer containing 50% formamide, 600mM NaCl, 80mM Tris-HCl (pH 7.5), 4mM 
EDTA, 0.1% pyrophosphate, 0.2mg/ml heparin sulfate, and 10% dextran sulfate. Slides 
were covered with coverslips and incubated at 37°C in a humid chamber for 22-24 
hours. After hybridization the coverslips were removed in 1X SSC (saline sodium 
citrate solution) and the sections were washed 4x15 minutes in 2X SSC/50% formamide 
at 43-44°C, followed by two 30 min washes with 1X SSC at room temperature. The 
slides were rapidly rinsed in distilled water and then in 70% ethanol. 
The sections were dried and exposed to Kodak-Biomax MR Autoradiographic film 
(Sigma-Aldrich, Milano, Italy). A slide containing a reference scale of 16 known 
amounts of 
14
C standards (ARC-146C, American Radiolabeled Chemical, Inc., St. 
Louis, MO, USA) was co-exposed with the samples. The autoradiographic films were 
exposed in a time range of 14-30 days depending from the probe and the specific brain 
region to be analyzed . The optimal time of exposure was chosen to maximize signal-to-
noise ratio but to prevent optical density from approaching the limits of saturation. Film 
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development protocol included a 1.5 min dip in the developer solution and 3 min in the 
fixer. 
 
Data analysis. 
The quantitation of the autoradiographic signal was performed using a computerized 
image analysis system including: a transparency film scanner (Microtek Europe B. V., 
Rotterdam, The Netherlands), an Apple iMac Intel Core 2 Duo  3,06GHz 3MB cache 
4GB SDRAM DDR3 a 1066MHz, and ImageJ software (v. 1.40, Rasband, W.S., 
http://rsb.info.nih.gov/ij/). Sections on film were captured individually. The original 
characteristics of the scanned images (i.e. contrast, brightness, resolution) were 
preserved. Each experimental group contained 4-6 animals. Each slide contained 3 
adjacent sections of a single animal. All hybridized sections were exposed on the same 
sheet of X-ray film. Signal intensity analysis was carried out on digitized 
autoradiograms measuring mean optical density (trasmittance) within outlined Regions 
of Interest (ROIs) in correspondence of the cortex, caudate-putamen and nucleus 
accumbens. These cortical and striatal subregions are structurally and functionally 
interconnected through projections from the cortex, which targets specific striatal 
sectors. ROIs in the cortex were selected based on recent data describing functional and 
anatomical correlation between cortical and striatal subregions (Willuhn et al., 2003). 
ROIs in the striatum have been chosen according to classical subdivision of this region 
(Steiner and Gerfen 1993). 
An oval template, proportional to the dimensions of the anatomical subregion, was used 
for computerized quantitations in each one of the ROIs depicted. 
Sections were quantitated blind to the treatment conditions. In order to test for inter-
observer reliability, an independent quantitation was performed by a second 
investigator. Results obtained by the first investigator were considered reliable, and then 
reported, only when they were quantitatively comparable, in terms of consistency of the 
statistically significant effects found, to that obtained by the second investigator. 
Measurements of mean optical density within ROIs were converted using a calibration 
curve based on the standard scale co-exposed to the sections. 
14
C standard values from 4 
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through 12 were previously cross-calibrated to 
35
S brain paste standards, in order to 
assign a dpm/mg tissue wet weight value to each optical density measurement through a 
calibration curve. For this purpose a “best fit” 3rd degree polynomial was used. For each 
animal, measurements from the 3 adjacent sections were averaged and the final data 
were reported in relative dpm as mean ± S.E.M. 
One-way Analysis of Variance (ANOVA) was used to analyze treatment effects. The 
Tukey’s post hoc test was used to determine the locus of effects in any significant 
ANOVA.  
A comparison between groups with same treatment, but different first treatment, in 
order to analyze the effect of the last one, were carried out by Student’s t test. In all 
tests, significance was set at p>0.05 (two-tailed).  
To calculate the Homer1a/Homer1b/c ratio we first divided the mean value of Homer1a 
and Homer1b/c mRNA expression to the correspondent value of vehicle mRNA 
expression in each region. The normalized Homer1a value of expression was then 
divided for normalized Homer1b/c value of expression. A result >1 indicated prominent 
Homer1a over Homer1b/c expression; a result <1 indicated prominent Homer1b/c over 
Homer1a expression (de Bartolomeis et al., 2013). 
To determine whether gene expression differed between the ROIs, measurements from 
each treatment group were taken as the dependent variable, and the ROIs in which 
expression was measured as the independent variable (i.e.: measurements were analyzed 
per region effect). As distribution of measurements values did not follow a normal 
distribution (as assessed by the Shapiro-Wilk test), the non-parametric Kruskal-Wallis 
test was used to investigate the null hypothesis that no significant differences could be 
found in mRNA expression throughout cortical or striatal subregions. Significant 
differences among groups were analyzed by the Wilcoxon test for multiple comparisons 
(Iasevoli et al., 2014). In a subsequent step we used Two Way Analysis of Variance 
(ANOVA) in order to evaluate first treatment effect, second treatment effect and the 
interaction between first treatment and second treatment effect on gene expression. So 
we investigated whether the observed gene expression was mainly induced by first 
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treatment effect or by second treatment effect or by first treatment*second treatment 
interaction. 
 
 
PRELIMINAR DATA 
In the acute paradigm Homer1a is induced by amisulpride at both doses compared to 
control in ventral and medial striatal subregions, even though in a no statistically 
significant manner (AMS35 vs VEH and AMS10 vs VEH). Haloperidol induced 
Homer1a in dorsolateral subregion of caudate-putamen compared to all other treatment 
(hal vs ams35, ams10, veh), in ventrolateral subregions compared to veh and ams35 (hal 
vs veh, ams35), in dorsomedial subregions compared to vehicle (hal vs veh). No 
significant Homer1a induction by haloperidol or amisulpride was detected in the cortex 
(ANOVA, p<0.05).  In the acute paradigm we analyzed Immediate Early Genes 
expression induced by haloperidol and amisulpride at two different doses: 10mg/kg and 
35 mg/kg. So, we identified in the striatum, a peculiar pattern of expression induced by 
haloperidol, mainly impacting lateral subregions and by amisulpride at high doses, 
mainly impacting medial subregions. Specifically we observed that, after acute 
administration,   in the lateral subregions of the striatum Immediate Early Genes 
expression was prevalently induced by haloperidol as compared to vehicle and to 
amisulpride, both at low doses (10 mg/kg) and at high doses (35 mg/kg). Specifically, 
we analyzed the expression of Immediate Early Genes Homer1a, Ania3, its splicing 
variant, Arc, Zif-268 and c-fos  that had been demonstrated to be involved in synaptic 
plasticity and to be affected by antipsychotic treatment. In agreement with our previous 
work (Ambesi-Impiombato et al.,2007; Tomasetti et al.,2007), we showed that 
haloperidol acute administration significantly induced the expression of Immediate 
Early Genes Homer1a, Ania-3, its splicing variant, Arc, Zif-268, compared to vehicle, in 
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lateral striatal subregions. However, the extent of Immediate Early Genes induction by 
haloperidol in medial regions was lesser than in lateral regions, never reaching 
statistical significance. In the opposite of haloperidol, amisulpride at high dose 
(35mg/kg) induced a significant  expression of the Immediate Early Genes Homer1a, 
Ania-3, Arc and Zif-268 that was restricted to medial regions of caudate-putamen, 
compared to vehicle. Indeed, a statistically significant induction of c-fos and Zif-268 
transcripts expression, but not of the other genes, was highlighted by amisulpride 
10mg/kg in medial striatal regions, compared to vehicle. Altogether, results suggest that 
haloperidol and amisulpride trigger different patterns of Immediate Early Genes 
expression in the striatum, with a prevailing effect of haloperidol in the lateral 
subregions and a more definite dose-dependent impact of amisulpride in the medial 
subregions. In the cortex, the expression of Immediate Early Genes was poorly affected 
by haloperidol or amisulpride administration. Indeed,  Homer1a expression was induced 
by haloperidol compared to vehicle in the ACC, whereas amisulpride at low doses 
reduced the expression of the gene in the MC. Arc expression was significantly induced 
by haloperidol compared to vehicle in the I. These results confirm previous findings in 
which haloperidol acute administration demonstrated a weak impact on cortical gene 
expression. Moreover, amisulpride, like haloperidol, showed a low effect on Immediate 
Early Genes expression in the cortex, probably due to its poor impact on serotoninergic 
neurotransmission. Topographic analysis confirmed the impact of antipsychotic 
treatment on Immediate Early Genes distribution along cortical and subcortical regions. 
Resembling the results of quantitative analysis of gene expression, haloperidol and 
amisulpride differently affected radioactive signal distribution in the cortex and in the 
striatum. Specifically, haloperidol administration induced a signal peak in the lateral 
subregions of the striatum, consistently with prominent action of this compound on 
motor performances. On the contrary, amisulpride administration induced a signal peak 
in the medial striatal subregions, that was highly pronounced for the 35 mg/kg dose. 
Prominent medial induction of Immediate Early Genes expression by amisulpride may 
be consistent with its proposed action on limbic structures and with its lower propensity 
to induce motor side effects, compared to haloperidol. In the cortex, antipsychotic 
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treatment elicited poor changes in the topographic distribution curves of Immediate 
Early Genes analyzed. Given the distinct and specific impact on Immediate Early Genes 
expression by amisulpride and haloperidol in striatal regions, as observed by both 
quantitative and topographic analyses, we hypothesized that the two antipsychotics may 
exert prevailing action in two macro-regions of interest, corresponding to discrete 
medial and lateral regions of striatum with peculiar anatomic and functional connections 
(Steiner and Gerfen,1993; Willuhn et al.,2003) that were different from the ROIs we 
originally used. Therefore, we carried out adjunctive quantitative analysis of gene 
expression by haloperidol and the two doses of amisulpride in these macro-areas of the 
striatum. So, we observed that 1) haloperidol induced Immediate Early Genes 
expression prominently in lateral striatal regions, which are targeted by cortical areas 
that control motor and visuo-spatial behaviors (Featherstone and McDonald, 2004); 2) 
amisulpride, at high dose, mainly triggered Immediate Early Genes expression in medial 
aspects of striatum, which have been implicated in reward, motivation, and goal-
directed learning (Graybiel, 2008). 
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PICTURE 2. Model of the del of the peculiar pattern of gene induction in striatum by amisulpride, at both 
10 and 35 mg/kg doses, compared to haloperidol.. The selected area in each autoradiographic image has 
been magnified on the right. No other adjustments have been carried out on the images. On the right side 
of the picture we have provided a diagram with the adjunctive ROIs (Lst, lateral striatum, and Mst, 
medial striatum) that have been considered for the further quantitative evaluation.  
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RESULTS 
In order to better recapitulate the results of the study, in a first step I’ll present, for each 
gene: 1) quantitative analysis of genes expression, first in the striatum and then in the 
cortex. For each gene, I’ll consider separately groups that had received vehicle as first 
treatment or haloperidol as first treatment, focusing on differences between groups 
(One-Way ANOVA); 2) a comparison between gene expression induced by treatment 
preceded by vehicle as first treatment, with gene expression induced by the same 
treatment preceded by haloperidol as first treatment (Student’s t); 3) treatment effect, 
first treatment effect or interaction between first treatment and second treatment effect, 
assessed by Two-Way ANOVA. In a second step, I’ll present 4) topographic analysis in 
the cortex and in the striatum showing the differences in genes expression throughout 
cortical and subcortical regions among groups; 5) Homer1a/Homer1b ratio.  
 
HOMER1A  
STRIATUM. In the experimental groups treated by vehicle as first treatment, a 
statistically significant Homer1a induction were found in all striatal subregions, with 
the exception of Sab (ANOVA: DM, p<.0001, df=2,9, F=36.3; DL, p=.0008, df=2,9, 
F=17.6; VM, p=.0008, df=2,9, F=17.4; VL, p=.022, df=2,9, F=5.9; CAb, p=.016, 
df=2,9, F=6.6; SAb, p>.05, df=2,9).  
Veh/ams significantly induced Homer1a  compared to veh/veh in DM, DL, VM e Cab 
(Tukey’s: p<.0001; p=.003; p=.0006; p=.013, respectively). Homer1a mRNA signal 
was enhanced in a statistically significant manner by veh/hal compared to veh/veh in 
DM, DL, VM, VL (Tukey’s:  p=.0002; p=.0009; p=.029; p=.023, respectively). No 
significant differences were found between veh/ams and veh/hal in any striatal 
subregions (Tukey’s: p>.05). 
In the experimental groups treated by haloperidol as first treatment, statistically 
significant differences were found in the DM, DL, and VL (ANOVA: DM, p=.041, 
df=2,10, F=4.4; DL, p=.002, df=2,10, F=11.5; VM, p>.05, df=2,10; VL, p=.012, 
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df=2,10, F=6.9; CAb, p>.05, df=2,10; SAb, p>.05, df=2,10). Hal/ams did not induce 
Homer1a expression compared to hal/veh in all caudate-putamen subregions and 
nucleus accumbens (Tukey’s: p>.05). On the contrary, Homer1a expression was 
significantly induced by hal/hal compared to hal/veh in DM, DL, VL  (Tukey’s: p=.043; 
p=.002; p=.011, respectively), and compared to hal/ams in the DL and VL (Tukey’s: 
p=.007; p=.038).  
Comparing groups with same treatment, but different first treatment, we observed that 
Homer1a expression was statistically significant induced by veh/ams compared to 
hal/ams in the DL, VM, and VL (Fig. 4B; Student’s t; DM, p>.05, df=1,7; DL<.0001, 
df=1,7, F=80.3; VM, p=.031, df=1,7, F=7.2; VL, p=.044, df=1,7, F=5.9; CAb, p>.05, 
df=1,7; SAb, p>.05, df=1,7). No significant differences were found between hal/veh and 
veh/veh, and between hal/hal and veh/hal in the striatum (Student’s t: p>.05, df=1,7 in 
all regions). Thus, in the striatum haloperidol first treatment prevented amisulpride to 
induce Homer1a, whereas expression of Homer1a by haloperidol was not significantly 
affected by first treatment. 
Two-way ANOVA revealed that Homer1a expression was not significantly affected by 
first treatment in the striatum (first treatment effect: DM: p>0.05, F=1.05, df=1,19; DL: 
p>0.05, F=1.65, df=1,19; VL: p>0.05, F=0.01, df=1,19; VM p>0.05, F=0.33, df=1,19; 
CAb: p>0.05, F=0.67, df=1,19; SAb=: p>0.05, F=0.04, df=1,19). Gene expression was 
significantly affected by treatment in all caudate putamen subregions and in CAb 
(second treatment effect: DM: p<0.0001, F=16.64, df=2,19; DL: p<0.0001, F=24.81, 
df=2,19; VL: p<0.001, F=11.96, df=2,19; VM: p<0.01, F=9.73, df=2,19; CAb: p<0.01, 
F=3.53, df=2,19; SAb: p>0.05, F=3.09, df=2,19). In DL, Homer1a expression was also 
affected by the combination of first and second treatment (first treatment*second 
treatment effect: DM: p>0.05, F=1.17, df=2,19; DL: p<0.0001, F=24.81, df=2,19; VL: 
p<0.001, F=11.96, df=2,19; CAb: p<0.05, F=3.53, df=2,19; SAb: p>0.05, F=3.01, 
df=2,19).  
CORTEX. In the experimental groups treated by vehicle as first treatment, statistically 
significant differences in Homer1a expression were observed in all cortical regions 
(ANOVA, ACC: p=.001, df=2,9, F=15.9; MAC: p=.002, df=2,9, F=11.9; MC: p=.003, 
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df=2,9, F=11.3; SS: p=.005, df=2,9, F=9.5; IC: p<.0001, df=2,9, F=39.5). In all cortical 
subregions considered, veh/ams induced Homer1a expression compared to veh/veh 
(Tukey’s: ACC, p=.0008; MAC, p=.002; MC, p=.002; SS: p=.005; IC: p<.0001), and by 
veh/hal compared to veh/veh in the MC (Tukey’s, p=.032). Homer1a expression was 
also significantly induced by veh/ams compared to veh/hal in the ACC (Tukey’s, 
p=.035), SS (Tukey’s, p=.041), and IC (Tukey’s, p=.0001). In the experimental groups 
treated by haloperidol as first treatment, no significant differences among groups were 
found (ANOVA, ACC: p>.05, df=2,10; MAC: p>.05, df=2,10; MC: p>.05, df=2,10; SS: 
p>.05, df=2,10; IC: p>.05, df=2,10).  
Comparing groups with same treatment, but different first treatment, had revealed that 
veh/ams significantly induced Homer1a expression compared to hal/ams in all cortical 
regions (Student’s t: ACC, p=.0007, df=1,7, F=32.8; MAC, p=.0002, df=1,7, F=46.9; 
MC: p=.004, df=1,7, F=16.7; SS, p=.007, df=1,7, F=13.5; IC, p=.004, df=1,7, F=17.6). 
No significant differences were found between hal/veh and veh/veh, and between 
hal/hal and veh/hal in the striatum (Student’s t: p>.05, df=1,7 in all regions). 
Thus, in the cortex, such as in the striatum, haloperidol first treatment prevented 
amisulpride to induce Homer1a; on the contrary Homer1a expression was limitedly 
affected by haloperidol.  
In the cortex we highlighted a significant interaction effect between first treatment and 
second treatment. Specifically amisulpride treatment affected Homer1a expression 
following vehicle first treatment, whereas did not when preceded by haloperidol 
treatment (first treatment*second treatment effect: ACC: p<0.05, F=5.38, df=1,19; 
MAC: p<0.05, F=8.91, df=1,19; MC: p<0.05, F=8,59, df=1,19; SS: p<0.05, F=6.24, 
df,19; IC: p<0.05, F=5.66, df=1,19). No first or second treatment effect were detected in 
all subregions considered (first treatment effect: ACC: p>0.05, F=0.65, df=1,19; MAC: 
p>0.05, F=2.17, df=1,19; MC: p>0.05, F=2.47, df=1,19; SS: p>0.05, F=0.84, df=1,19; 
IC: p>0.05, F=0,17, df=1,19; second treatment effect: ACC: p>0.05, F=3.22, df=1,19; 
MAC: p>0.05, F=0.91, df=1,19; MC: p>0.05, F=1.12, df=1,19; SS: p>0.05, F=2.11, 
df=1,19; IC=p>0.05, F=5.66, df=1,19).  
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PICTURE 3.  A. Homer1a mRNA expression (in relative dpm means ± standard error means) and in 
cortical (above) and striatal (below) regions. *=Tukey’s post-hoc test, p<.05, vs. vehicle. **=Tukey’s 
post-hoc test, p<.05, vs. all treatments. B. Distribution of Homer1a expression throughout cortical 
(above) and striatal (below) in rats receiving vehicle, haloperidol, or amisulpride as second treatment. *= 
Student’s t test, p<.05.  
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ARC 
STRIATUM. In the experimental groups treated by vehicle as first treatment, significant 
differences were found in the DM, DL, and VL (ANOVA: DM, p=.015, df=2,9, F=6.9; 
DL, p=.003, df=2,9, F=11.5; VM, p>.05, df=2,9; VL, p=.004, df=2,9, F=10.7; CAb, 
p>.05, df=2,9; SAb, p>.05, df=2,9). Arc expression was not significantly increased by 
veh/ams in all striatal subregions (Tukey’s: p>.05). In DM, DL e VL, veh/hal induced 
Arc expression compared to veh/veh (Tukey’s: DM, p=.012; DL, p=.002; VL, p=.003). 
No statistically significant differences  was detected in the striatum between veh/hal and 
veh/ams (Tukey’s: p>.05).  
In the experimental groups treated by haloperidol as first treatment, statistically 
significant differences in Arc expression were found in all caudate-putamen regions 
(ANOVA: DM, p=.014, df=2,8, F=7.5; DL, p=.002, df=2,8, F=14.8; VM, p=.001, 
df=2,8, F=15.1; VL, p=.0007, df=2,8, F=20.7), but not in the nucleus accumbens 
(ANOVA: CAb, p>.05, df=2,8; SAb, p>.05, df=2,8). 
Arc expression was significantly induced by hal/hal and hal/ams compared to hal/veh in 
the medial caudate-putamen (Tukey’s: DM, p=.025 and p=.024, respectively; VM, 
p=.011 and p=.002, respectively), and by hal/hal compared to both hal/veh (Tukey’s: 
DL, p=.001; VL, p=.0006) and hal/ams (Tukey’s: DL, p=.013; VL, p=.005) in the 
lateral caudate-putamen. 
Comparing groups with same treatment, but different first treatment, we had found that 
hal/ams significantly induced specifically  Arc expression compared to veh/ams in the 
VM (Student’s t: p=.036, df=1,5, F=7.9). No other significant differences were 
observed between veh/ams and hal/ams (Student’s t: p>.05, df=1.5 in all subregions 
with the exclusion of VM), between veh/hal and hal/hal (Student’s t: p>.05, df=1.6 in 
all subregions), and between veh/veh and hal/veh (Student’s t: p>.05, df=1.6 in all 
subregions).   
Indeed, the pattern of Arc expression by antipsychotics in striatum was not substantially 
affected by the type of first treatment, vehicle or haloperidol.  
 23 
 
In all subregions of striatum no significant intergroups differences in Arc expression 
were observed depending on first chronic treatment (first treatment effect: DM: p>0.05, 
F=1.05, df=1,17; DL: p>0.05, F=1.65, df=1,17;  VL: p>0.05, F=11.96, df=1,17; CAb: 
p>0.05, F=0.67, df=1,17; SAb: p>0.05, F=0.04, df=1,17).  
In the striatum second chronic treatment significantly impacted Arc expression. 
Specifically in lateral striatal subregions haloperidol second treatment induced Arc 
expression compared to amisulpride and control, whereas in medial subregions only 
compared to control (second treatment effect: DM: p<0.001, F=16.64, df=2,17; DL: 
p<0.0001, F=24.81, df=2,17; VL: p<0.001, F=11.95, df=2,17; VM: p<0.01, F=9.73, 
df=2,17; CAb: p<0.05, F=3.53, df=2,17; SAb: p>0.05, F=3.09, df=2,17).  
No interaction effect between first and second treatment was observed impacting Arc 
expression (first treatment*second treatment  effect: DM: p>0.05, F=1.04, df=2,17; DL: 
p>0.05, F=1.94, df=2,17; VL: p>0.05, F=1.49, df=2,17; VM: p>0.05, F=2.24, df=2,17; 
CAb: p>0.05, F=0.78, df=2,17; SAb: p>0.05, F=0.71, df=2,17).  
CORTEX. In both first treatment groups (haloperidol or vehicle), no significant inter-
group differences in Arc expression were found in cortical regions (ANOVA: p>.05, 
df=2,9 in all cortical regions in groups treated by vehicle as the first treatment; p>.05, 
df=2,8 in all cortical regions in groups treated by haloperidol as the first treatment). No 
significant differences in Arc expression were observed comparing groups with same 
treatment, but different pretreatment, between veh/ams and hal/ams (Student’s t: p>.05, 
df=1,5 in all regions), between veh/hal and hal/hal (Student’s t: p>.05, df=1.6 in all 
regions), and between veh/veh and hal/veh (Student’s t: p>.05, df=1.6 in all regions).     
Therefore, Arc expression in the cortex was not affected by antipsychotics after either 
paradigms of first treatment. No changes in Arc expression was observed when second 
treatment was preceeded by haloperidol or vehicle first treatment (first treatment effect: 
ACC: p>0.05, F=0.08, df=1,17, MAC: p>0.05, F=0.74, df=1,17; MC: p>0.05, F=1.82, 
df=1,17; SS: p>0.05, F=3.62, df=1,17; IC: p>0.05, F=0.58, df=1,17; second treatment 
effect: ACC: p>0.05, F=0.41, df=2,17; MAC: p>0.05, F=0.84, df=2,17; MC: p>0.05, 
F=0.51, df=2,17; SS: p>0.05, F=1.15, df=2,17; IC: p>0.05, F=2.52, df=2,17). Indeed no 
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interaction effect was detected between first and second treatment in any cortical 
subregions considered (first treatment*second treatment: ACC: p>0.05, F=0.41, 
df=2,17; MAC: p>0.05, F=0.03, df=2,17; MC: p>0.05, F=0.51, df=2,17; SS: p>0.05, 
F=1.11, df=2,17; IC: p>0.05, F=0.81, df=2,17). 
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PICTURE 4. A.  Arc mRNA expression (in relative dpm means ± standard error means) in cortical (above) 
and striatal (below) regions. *=Tukey’s post-hoc test, p<.05, vs. vehicle. **=Tukey’s post-hoc test, p<.05, 
vs. all treatments. B. Distribution of Arc expression throughout cortical (above) and striatal (below) 
regions in rats receiving vehicle, haloperidol, or amisulpride as second treatment. *= Student’s t test, 
p<.05.  
 26 
HOMER1B 
STRIATUM. In the experimental groups treated by vehicle as first treatment, significant 
inter-group differences in Homer1b/c expression were found in the VL only (ANOVA: 
DM, p>.05, df=2,8; DL, p>.05, df=2,8; VM, p>.05, df=2,8; VL, p=.004, df=2,8, 
F=14.9: CAb, p>.05, df=2,8; SAb, p>.05, df=2,8). In this subregion, Homer1b/c 
expression by both veh/veh and veh/hal was significantly higher than that by veh/ams 
(Fig. 6A; Tukey’s: p=.035 and p=.004, respectively).  
In the groups treated by haloperidol as first treatment, significant inter-group 
differences in Homer1b/c expression were found in all striatal subregions, with the 
exception of the VL (ANOVA: DM, p=.003, df=2,7, F=5.3; DL, p=.016, df=2,7, F=7.7; 
VM, p=.021, df=2,7, F=7.1; VL, p>.05, df=2,7; CAb, p=.014, df=2,7, F=8.2; SAb, 
p=.019, df=2,7, F=7.3). Homer1b/c expression was significantly increased by hal/ams 
compared to hal/hal and hal/veh in DL (Tukey’s; p=.041 and p=.018, respectively), VM 
(Tukey’s; p=.033 and p=.031, respectively), and CAb (Tukey’s; p=.043 and p=.014, 
respectively), and compared to hal/veh only in the DM (Tukey’s: p=.037) and SAb 
(Tukey’s: p=.018). No significant differences between hal/hal and hal/veh were found. 
Comparing groups with same treatment, but different first treatment, we observed that 
Homer1b/c expression was significantly higher in the hal/ams group compared to 
veh/ams in all striatal subregions (Student’s t: DM, p=.011, df=1,6, F=20.9; DL, 
p=.006, df=1,6, F=28.2; VM, p=.002, df=1,6, F=46.3; VL, p=.003, df=1,6, F=38.8; 
CAb,  p=.004, df=1,6, F=32.7; SAb, p=.013, df=1,6, F=17.5). No statistically 
significant differences were detected between veh/hal and hal/hal (Student’s t: p>.05, 
df=1,6 in all subregions), and between veh/veh and hal/veh (Student’s t: p>.05, df=1,6 
in all subregions).  
Thus, Homer1b/c expression was mainly increased by amisulpride compared to 
haloperidol. Amisulpride-mediated increase was significantly higher after haloperidol 
first treatment than after vehicle first treatment.   
Two-way ANOVA revealed a first treatment effect on the Homer1b expression in DL 
and VM (first treatment effect: DM: P>0.05, F=3.29, df=1,13; DL: p<0.05, F=5.19, 
df=1,13; VL: p>0.05, F=3.46, df=1,13; VM: p<0.05, F=7.11, df=1,13; CAb: p>0.05, 
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F=5.72, df=1,13; SAb: p>0.05, F=4.44, df=1,13). Specifically in DL and in VM 
haloperidol first treatment significantly affected Homer1b expression compared to 
vehicle first treatment. No second treatment effect on Homer1b expression was detected 
in the striatum (second treatment effect: DM: P>0.05, F=1.04, df=2,13; DL: p>0.05, 
F=3.11, df=2,13; VL: p>0.05, F=1.29, df=2,13; VM: p>0.05, F=1.91, df=2,13; CAb: 
p<0.05, F=6.01, df=2,13; SAb: p>0.05, F=3.63, df=2,13). In DL, in ventral striatal 
subregions and in nucleus accumbens Two-way ANOVA showed an interaction effect 
between first and second chronic treatment: amisulpride enhanced Homer1b expression 
when preceeded by haloperidol as first treatment, whereas following vehicle first 
treatment did not (first treatment*second treatment effect: DM: P>0.05, F=1.04, 
df=2,13; DL: p<0.05, F=9.54, df=2,13; VL: p<0.05, F=9.24, df=2,13; VM: p<0.05, 
F=10.32, df=2,13; CAb: p<0.05, F=5.72, df=2,13; SAb: p<0.05, F=4.15, df=2,13).  
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PICTURE 5. A. Homer1b/c mRNA expression (in relative dpm means ± standard error means) and in 
cortical (above) and striatal (below) regions. *=Tukey’s post-hoc test, p<.05, vs. vehicle. **=Tukey’s 
post-hoc test, p<.05, vs. all treatments. B. Distribution of Homer1b/c expression throughout cortical 
(above) and striatal (below) regions in rats receiving vehicle, haloperidol or amisulpride as second 
treatment. *= Student’s t test, p<.05.  
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PSD-95 
STRIATUM. No significant inter-group differences in PSD-95 expression were found in 
groups treated by vehicle as first treatment (ANOVA: p>.05, df=2,9 in all striatal 
regions) or haloperidol as first treatment (ANOVA: p>.05, df=2,9 in all cortical and in 
all striatal regions).  
Comparing groups with same second treatment and different first treatment, we found 
that PSD-95 expression was significantly higher by veh/veh compared to hal/veh in the 
DL (Student’s t: p=.038, df=1,6, F=7.8), VM (Student’s t: p=.036, df=1,6, F=7.9), and 
VL (Student’s t: p=.031, df=1,6, F=8.9). No other significant differences were found 
between these treatment groups. No significant differences between veh/ams and 
hal/ams were observed (Student’s t: p>.05, df=1,6 in all regions).    
Therefore, PSD-95 expression may be reduced by chronic treatment by haloperidol, 
while it may be unaffected by amisulpride. Haloperidol or vehicle first chronic 
treatment did not impact Psd-95 mRNA expression level in the striatum (first treatment 
effect: DM: P>0.05, F=1.21, df=1,18; DL: p>0.05, F=0.14, df=1,18; VL: p>0.05, 
F=2.21, df=1,18; VM: p>0.05, F=2.69, df=1,18; CAb: p>0.05, F=0.93, df=1.18; SAb: 
p>0.05, F=0.11, df=1,18; second treatment effect: DM: P>0.05, F=0.34, df=2,18; DL: 
p>0.05, F=0.53, df=2,18; VL: p>0.05, F=1.59, df=2,18; VM: p>0.05, F=0.63, df=2,18; 
CAb: p>0.05, F=0.04, df=2.18; SAb: p>0.05, F=0.29, df=2,18). No interaction effect on 
PSD-95 expression was observed between first and second treatment (first 
treatment*second treatment effect: DM: P>0.05, F=2.03, df=2,18; DL: p>0.05, F=2.83, 
df=2,18; VL: p>0.05, F=2.84, df=2,18; VM: p>0.05, F=2.36, df=2,18; CAb: p>0.05, 
F=0.31, df=2.18; SAb: p>0.05, F=0.45, df=2,18).  
CORTEX. No significant differences among experimental groups in PSD-95 expression 
were found both in groups treated by vehicle as first treatment (ANOVA: p>.05, df=2,9 
in all cortical regions) and in those treated by haloperidol as first treatment (ANOVA: 
p>.05, df=2,9 in all cortical regions).  
Comparing groups treated by same second treatment, but different first treatment, we 
found that PSD-95 expression was significantly higher by veh/hal compared to hal/hal 
in the MAC (Student’s t: p=.006, df=1,7, F=15.1), MC (Student’s t: p=.028, df=1,7, 
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F=7.5), and IC (Student’s t: p=.025, df=1,7, F=7.9), and by veh/veh compared to 
hal/veh in the DL (Student’s t: p=.038, df=1,6, F=7.8), VM (Student’s t: p=.036, df=1,6, 
F=7.9), and VL (Student’s t: p=.031, df=1,6, F=8.9). No other significant differences 
were found between these treatment groups. No significant differences between 
veh/ams and hal/ams were observed (Student’s t: p>.05, df=1,6 in all regions).    
Also in cortical subregions, PSD-95 expression may be affected by chronic treatment 
with haloperidol, while by amisulpride did not.  
In the cortex Psd-95 expression level did not change after haloperidol or amisulpride 
treatment. Haloperidol chronic first administration did not impact Psd-95 expression, 
compared to vehicle first treatment. No statistically significant difference was observed 
between veh/ams and hal/ams or between veh/hal and hal/hal in all cortical subregions 
(ACC: p>0.05, F=0.62, df=5,18; MAC: p>0.05, F=1.18, df=5,18; MC: p>0.05, F=0.81, 
df=5,18; SS: p>0.05, F=0.83, df=5,18; IC: p>0.05, F=2.08, df=5,18). 
No first or second treatment effect on Psd-95 expression was found (first treatment 
effect: ACC: P>0.05, F=0.67, df=1,18; MAC: p>0.05, F=3.17, df=1,18; MC: p>0.05, 
F=1.53, df=1,18; SS: p>0.05, F=1.84, df=1,18; IC: p>0.05, F=1.46, df=1,18; second 
treatment effect: ACC: P>0.05, F=0.26, df=2,18; MAC: p>0.05, F=0.37, df=2,18; MC: 
p>0.05, F=0.64, df=2,18; SS: p>0.05, F=0.84, df=2,18; IC: p>0.05, F=2.46, df=2,18). 
Moreover two-way ANOVA did not revealed any first and second treatment interaction 
effect on gene expression in the cortex (first treatment*second treatment effect: ACC: 
P>0.05, F=0.97, df=2,18; MAC: p>0.05, F=0.86, df=2,18; MC: p>0.05, F=0.65, 
df=2,18; SS: p>0.05, F=0.35, df=2,18; IC: p<0.05, F=2.43, df=2,18).  
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PICTURE 6. A. Psd-95 mRNA expression (in relative dpm means ± standard error means) and in cortical 
(above) and striatal (below) regions. B. Distribution of Psd-95 expression throughout cortical (above) and 
striatal (below) regions in rats receiving vehicle, haloperidol or amisulpride as second treatment. *= 
Student’s t test, p<.05.  
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TOPOGRAPHICAL ANALYSIS  
STRIATUM. In topographical analysis we have described spatial distribution of gene 
expression along striatal and cortical subregions following different treatment paradigm. 
In each analysis we compared two experimental groups treated with the same second 
treatment but different first treatment, in order to individuate where haloperidol first 
treatment impacts topographic distribution of genes induced by typical and atypical 
antipsychotic.  
In antipsychotic-naïve groups , Homer1a mRNA signal distribution by vehicle and 
amisulpride was homogeneous (Kruskal-Wallis: p>.05, df=5), while treatment with 
haloperidol increased Homer1a expression in the caudate-putamen regions (Kruskal-
Wallis: p<.0001, df=5, : 30.5) compared to the nucleus accumbens. In the groups 
treated with  haloperidol as first treatment, signal distribution by vehicle and haloperidol 
was homogeneous throughout striatal regions (Kruskal-Wallis: p>.05, df=5). On the 
contrary, treatment by amisulpride increased Homer1a expression in the medial striatum 
(Kruskal-Wallis, p=.0004, df=5, : 22.8) compared to the lateral striatum and the 
nucleus accumbens.  
In antipsychotic-naïve rats, Arc mRNA signal was higher in the caudate-putamen 
regions compared to the nucleus accumbens regions by vehicle and haloperidol 
(Kruskal-Wallis: p<.0001, df=5, : 35.6 and p<.0001, df=5, : 39.7, respectively), while 
signal was homogeneously distributed throughout striatal regions in rats treated by 
amisulpride (Kruskal-Wallis: p>.05, df=5, : 6.7). In antipsychotic-treated rats, Arc 
mRNA signal distribution throughout striatal regions was homogeneous in rats treated 
by vehicle (Kruskal-Wallis: p>.05, df=5, : 9.1). Arc signal was significantly higher in 
the caudate-putamen compared to the nucleus accumbens regions in haloperidol and 
amisulpride-treated rats (Kruskal-Wallis: p=.0005, df=5, : 22.1 and p<.0001, df=5, : 
32.7, respectively).  
In antipsychotic-naïve rats, Homer1b/c mRNA signal was significantly higher in the 
lateral caudate-putamen compared to the nucleus accumbens regions after vehicle 
treatment (Kruskal-Wallis: p=.01, df=5, : 14.1) and in the VL compared to the nucleus 
 33 
accumbens regions after haloperidol treatment (Kruskal-Wallis: p=.02, df=5, : 12.6). 
Homer1b/c signal was homogeneously distributed throughout striatal regions after 
amisulpride treatment (Kruskal-Wallis: p>.05, df=5, : 4.4). In rats treated by 
haloperidol as the first treatment, Homer1b/c mRNA signal was significantly higher in 
DL, VM, and VL compared to the nucleus accumbens regions in the rats treated by 
vehicle (Kruskal-Wallis: p=.001, df=5, : 20.1). However, signal distribution was 
homogeneous throughout striatal regions in haloperidol and amisulpride-treated rats 
(Kruskal-Wallis: p>.05, df=5, : 6.2, and p>.05, df=5, : 5.9). 
PSD-95 mRNA signal distribution was homogeneous throughout striatal regions in all 
treatment groups (Kruskal-Wallis, veh/veh: p>.05, df=5, : 4.2; veh/hal: p>.05, df=5, : 
4.1; veh/ams: p>.05, df=5, : 4.3; hal/veh: p>.05, df=5, : 0.9; hal/hal: p>.05, df=5, : 
2.9; hal/ams: p>.05, df=5, : 0.3).  
CORTEX . In the groups treated by vehicle as first treatment, Homer1a mRNA signal 
distribution by vehicle and amisulpride was homogeneous (Kruskal-Wallis: p>.05, 
df=4, and p>.05, df=4, respectively), while treatment by haloperidol 
increased Homer1a expression in the MAC and MC compared to the ACC (Kruskal-
Wallis: p=.041, df=4, : 9.9). In the groups treated by haloperidol as the first treatment, 
signal distribution by all treatments was homogeneous throughout cortical regions 
(Kruskal-Wallis: p>.05, df=4). 
Signal of Arc, Homer1b/c, and PSD-95 mRNA was homogeneously distributed 
throughout cortical regions by all treatments groups.  
All together, data on topographic distribution confirm the difference in molecular 
effects of antipsychotics when given in previously-treated subjects compared to 
antipsychotic-naïve ones. 
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PICTURE 7. Illustrative autoradiograms of Homer1a, Arc, Homer1b/c, and PSD-95 mRNA expression in 
the cortex and the striatum.  
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HOMER1A/HOMER1B/C RELATIVE RATIO 
 
In the groups treated by vehicle as the first treatment the relative ratio was shifted 
toward Homer1a expression by haloperidol in the caudate-putamen, the MAC, and the 
MC. Amisulpride shifted the ratio toward Homer1a expression in all cortical and striatal 
regions.  
In the groups treated by haloperidol as the first treatment, haloperidol shifted the ratio 
toward Homer1a expression in striatum, while the genes’ relative expression was about 
equal in the cortex. Amisulpride treatment resulted in approximately equivalent relative 
gene expression or in some cortical regions shifted the ratio toward Homer1b/c 
expression. 
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PICTURE 8. Homer1a/Homer1b ratio.  
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TABLE 1. In this table two-way ANOVA results in the striatum are recapitulated. In red 
we have indicated statistically significant data.
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TABLE 2. In this table two-way ANOVA results in the cortex are recapitulated. In red we 
have indicated statistically significant data.
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DISCUSSION 
 
The present study is the first to explore at molecular level the common clinical 
treatment paradigm of “switching” between antipsychotics. Specifically, using gene 
expression as preclinical marker of antipsychotic action, we investigated the induction 
of Postsynaptic Density Immediate Early Genes and the topography of brain activation 
induced by an atypical antipsychotic treatment after prolonged treatment with a typical 
one. We focused on genes localized at crossroads of dopaminergic and glutamatergic 
system, related to psychosis, synaptic plasticity and demonstrated to be modulated by 
antipsychotics. We chose amisulpride as post-switch agent based on the evidence that, 
despite its high affinity for the D2R, comparable to haloperidol, showed low liability for 
extrapyramidal side effects, a clinical features of atypical antipsychotics. The results of 
the study are reported below, expounded point by point: 
1) In the acute paradigm, haloperidol induced a branded gene expression 
throughout the striatum, with a preferential impact on the lateral subregions; by 
contrast, the effect of amisulpride on gene expression was preferentially 
restricted to medial striatum (de Bartolomeis et al., 2013). So, modeling gene 
expression in animal model, haloperidol and amisulpride induced a peculiar and 
distinct pattern of Immediate Early Gene expression.  
It has been highlighted that the extent of Homer1a induction by antipsychotics may be 
related to the degree of D2R blockade of each drug (Iasevoli et al., 2009). So, it could be 
deduced  that the different pattern of Homer1a induction by haloperidol or amisulpride 
may be due to their distinct impact on dopamine receptors, with haloperidol inducing a 
stronger postsynaptic D2R blockade than amisulpride, whereas amisulpride 
preferentially act on presynaptic D2/D3R at low doses and on both pre-and postsynaptic 
D2/D3R at higher doses. Moreover amisulpride seems to preferentially act on D2R/D3R 
located in limbic and associative striatum (Stone et al., 2005). Indeed, it has been 
observed that induction of Homer1a may depend on the activation of NMDA receptors 
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and/or D1R-mediated signaling (Yamada et al., 2007; Sato et al., 2001). So, amisulpride 
and haloperidol may indirectly trigger Homer1a expression by blockade of D2Rs and 
concomitant activation of D1Rs by residual synaptic dopamine, which may in turn 
modulate glutamatergic neurotransmission at PSD level, regulating NMDA receptor 
activation (Borroto-Escuela et al., 2011). Indeed, the effect of haloperidol and 
amisulpride on gene expression seems to be restricted on striatal regions, in agreement 
with previous studies highlighting 5-HT2A receptors high affinity for the antipsychotics 
that specifically impact gene expression in the cortex, such as aripiprazole, ziprasidone 
and clozapine (Iasevoli et al., 2011a; Mo et al., 2005; Tomasetti et al., 2007). 
The peculiar pattern of Immediate Early Genes expression of amisulpride suggest a 
selectivity of this compound for limbic forebrain regions. The “molecular profile” of 
amisulpride may explain its ‘‘atypical’’ atypicality and provide a useful tool to address 
the molecular processes underlying clinical efficacy of atypical antipsychotics. 
2) The specific pattern of Immediate Early Genes expression induced by 
haloperidol and amisulpride held on after 15 days of treatment, in a chronic 
paradigm, when antipsychotic administration was preceded by vehicle first 
treatment. 
This finding are consistent with our previous observation that demonstrated a lacking 
sensitization of Homer1a after chronic treatment and suggests that both antipsychotics 
activate Homer-mediated postsynaptic glutamatergic signaling even after prolonged 
administration (Iasevoli et al., 2011). Notably, in a precedent study, we found no 
significant Homer1a induction by amisulpride in the cortex in the acute paradigm (de 
Bartolomeis et al., 2013). Therefore, amisulpride appears to trigger cortical Homer1a 
expression after a prolonged rather than an acute treatment. This feature may indicate 
the propensity of amisulpride to progressively activate glutamatergic signaling, and 
possibly neuronal depolarization, in the cortex during sustained treatments. It has been 
proposed that discrete glutamatergic activation may revert hypofrontality and decreased 
prefrontal activation, supposed in schizophrenia (Liemburg et al., 2012). Our results 
may partially explain the relative efficacy of amisulpride on negative symptoms 
(Arango et al., 2013). The impact of chronic amisulpride administration on cortical 
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glutamatergic signaling may depend on the action on D3 receptors. It has been observed 
that selective antagonists at D3 receptors increase extracellular levels of dopamine in the 
rat prefrontal cortex (Lacroix et al., 2003), most presumably by acting on inhibitory 
autoreceptors located on dopamine neurons of the ventral tegmental area. In turn, 
increased cortical dopamine may enhance NMDA receptor-mediated response via 
activation of D1 receptors (Tseng et al., 2004).  
3) In the switching group, where amisulpride treatment is preceded by haloperidol 
first treatment, haloperidol first treatment prevented amisulpride to induce 
Homer1a. Moreover, a prolonged administration of D2 strong blocker also 
affected the other Immediate Early Genes and constitutive gene expression. 
So, in animal model, the sequential antipsychotics administration affects brain 
transcripts in a significantly different manner compared to antipsychotic-naïve animals.  
One possible explanation for this finding is that chronic haloperidol treatment may lead 
to several molecular adaptations in dopaminergic and glutamatergic signaling: D2R up-
regulation (Varela et al., 2014); switch to D2R high-affinity status and/or in a condition 
of dopamine supersensitivity (Samaha et al., 2007; Seeman et al., 2007); altered AMPA 
or NMDA receptor trafficking (Fumagalli et al., 2008). Adaptations to prolonged 
haloperidol administration may partially change the molecular substrate where 
antipsychotic given subsequently acts, so giving rise to an unexpected downstream 
signaling. These results may suggest that the timing and the order by which 
antipsychotics are administered to subjects may substantially change their molecular 
action and the clinical outcome, such as efficacy and side effect.  
Indeed, this effect is more sharp in the striatum than in the cortex. These results suggest 
a differential activation of postsynaptic glutamatergic signaling induced by 
antipsychotic administration, based on previous treatments. A relevant translational 
consequence of these results is that amisulpride behaves differentially, at the molecular 
level, when given after a previous antipsychotic treatment or in antipsychotic-naïve 
subjects.  On the contrary, Homer1a induction by haloperidol didn’t depend on 
treatment length, so maintaining its molecular effect on postsynaptic glutamatergic 
signaling when given for a prolonged period of time.  
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The functional consequences of the Homer1a induction by antipsychotic in acute, 
chronic and switching paradigm are unknown. It has been demonstrated that Homer1a 
induction is involved in neuronal downscaling, thus preventing excessive postsynaptic 
depolarization, in neuronal population where it is expressed, i.e. GABAergic medium 
sized spiny neurons  (Tappe et al., 2006; Hu et al., 2010; Siddoway et al., 2014; Li et 
al., 2013). Intriguingly, medium spiny neurons are both intrastriatal interneurons and 
extrastriatal projecting fibers belonging to the output pathways implicated in motivated 
motor behavior (Kreitzer et al., 2008). Moreover, it has been demonstrated that striatal 
Homer1a expression may be implicated in motor control (Tappe et al., 2006). So, it 
could be hypotized that the functional result of Homer1a induction by antipsychotics 
may be a dopamine-induced glutamatergic regulation of GABAergic postsynaptic 
neurons and may indicate a putative effect on motor behaviours.  
The distinct preferential distribution of Immediate Early Genes induction by haloperidol 
and amisulpride seems to follow the regional functional specificity and, under the 
translational point of view, may account for the differences in the clinical profile of the 
two drugs. Several studies in animal model, by means of lesions or pharmacological 
blockade of dopamine signaling in specific regions, have demonstrated that 
dopaminergic projections to the ventro- and dorso- medial striatum are related to 
reward, motivation and goal-directed learning (Graybiel et al., 2008), whereas lateral 
striatum is involved in motor control, such as motor performances and visuo-spatial 
learning and memory (Featherstone and McDonald et al., 2004). Moreover, recent 
studies  showed a direct connection of medial striatum with central and lateral thalamic 
nucleus, which is in turn linked to prefrontal cortex and implicated in cognition and 
learning, as well as in neuropsychiatric disorders where cognitive tasks are impaired, 
such as schizophrenia (Shirvalkar et al., 2006; Smith et al., 2011). 
Indeed, a recent finding have reported that  haloperidol or amisulpride induced a 
coordinated gene expression in anatomically and functionally related cortico-striatal 
regions, even though with distinctive patterns. Haloperidol induced a coordinated 
corticostriatal gene expression prominently in regions related to motor performances (de 
Bartolomeis et al., 2013).These results are in line with the well-known propensity of 
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haloperidol to impact motor behaviors and to induce catalepsy at the dose used in this 
study (Wadenberg et al.,2001). Both doses of amisulpride triggered coordinated cortico-
striatal gene expression in both motor and limbic regions, thereby resulting in a more 
balanced gene induction, compared to haloperidol (de Bartolomeis et al., 2013). Taken 
together, these results account to the propensity of haloperidol to induce motor side 
effect in a dose-dependent manner (Kapur et al., 2001) and with a scarce or absent 
induction of motor impairment maybe triggered by the doses of amisulpride analyzed 
(Natesan etal.,2008).  
4) The effect of interaction between first and second treatment is more prominent 
in the dorsolateral caudate-putamen, compared to all other cortical and 
subcortical regions.  
These results suggest that haloperidol first treatment affects gene expression induced by 
amisulpride second treatment in a greater extent in dorsolateral subregion, compared to 
all other striatal subregion analyzed. These finding are in line with a previous 
observation that demonstrated a more sustained effect of haloperidol on gene expression 
in dorsolateral striatal subregion (Iasevoli, 2010).  
In switching group the effect of antipsychotic administration on the other genes 
analyzed are different from which induced by Homer1a.   
Arc expression was mainly induced by haloperidol, while limitedly by amisulpride. 
Indeed, haloperidol first treatment enhanced in a statistically significant manner Arc 
expression induced by amisulpride in medial striatal regions. Arc protein is involved in 
rapid cytoskeletal rearrangements secondary to a wide range of stimuli including to both 
glutamate and dopamine modulation (Bramham et al., 2008). So, also for Arc, the 
timing and the order in which antipsychotics are administered affect its expression. 
Moreover, the putatively biological effects on synaptic plasticity may be more sensitive 
to haloperidol than to amisulpride.  
Homer1b/c expression was significantly increased by chronic amisulpride compared to 
both vehicle and haloperidol-mediated levels, mainly in the striatum and when 
amisulpride was given in the subjects previously treated with haloperidol. Homer1b/c is 
the constitutive isoform of the Homer1 gene (de Bartolomeis et al., 2003), coding for a 
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scaffolding protein that bridge metabotropic glutamate receptors to their intracellular 
effectors and participates in the architecture of dendritic spines (Hayashi et al., 2009; de 
Bartolomeis et al., 2014). It has been observed that increased levels enrichment of 
Homer1b/c in the PSD is related to enlargement in dendritic spines shape and size (Sala 
et al., 2005; Sala et al., 2003; Sala et al., 2001). Therefore, it has been hypnotized that 
the increase of Homer1b/c after a chronic antipsychotic treatment may reinforce 
mGluR-mediated glutamatergic signaling and may trigger synaptic plasticity processes.  
Intriguingly, increase of Homer1b/c expression by amisulpride occurred when the 
compound was given in subjects pretreated with haloperidol but not in antipsychotic-
naïve ones, further reinforcing the view that the biological action of antipsychotics is 
crucially affected by prior antipsychotic treatment.  
Indeed, among other Immediate Early Genes, Homer1a showed a characteristic features 
such as 1) the extent of Homer1a induction by antipsychotics may be related to the 
degree of D2R blockade of each drug (Iasevoli et al., 2009); Homer1a induction hold on 
following chronic treatment (Iasevoli et al., 2011); in switching paradigm, the effect of 
a strong D2R blockade first treatment on Homer1a expression induced by amisulpride is 
more pronounced in dorsolateral subregions, where haloperidol impact in a greater 
extent. Taken toghether, these results suggest the  Homer1a is more sensitive as a 
molecular marker of antipsychotic treatment related to other Immediate Early Genes in 
acute, chronic and in switching paradigm.  
Homer1a and Homer1b/c exert opposite molecular functions on postsynaptic density, so 
the relative ratio of Homer1a/Homer1b/c levels has been demonstrated to affect 
mGluR-mediated signaling (Kammermeier et al., 2008), with substantial impact on PSD 
neurobiology, including synaptic plasticity (Ronesi et al., 2012; Sala et al., 2003; Sala et 
al., 2005). Relative ratio was shifted toward Homer1a in both the cortex and the 
striatum by both antipsychotic compounds when they were administered after a 
previously treated by vehicle. This result implicates that chronic haloperidol and 
amisulpride in antipsychotic-naïve subjects may preferentially elicit the biological 
actions mediated by Homer1a. However, in subjects previously treated by haloperidol, 
haloperidol shifted the ratio toward Homer1a in the striatum; moreover, amisulpride did 
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not affect the relative ratio of expression or shifted it toward Homer1b/c. Therefore, a 
previous treatment by an antipsychotic has a relevant and antipsychotic-specific effect 
on the direction of Homer1a/Homer1b/c-mediated molecular effects triggered by these 
compounds.   
Topographic analysis showed that haloperidol prominently induced gene expression in 
the medial agranular cortex, in the motor cortex, and in the lateral caudate-putamen, a 
regions related to motor side effect. This pattern of topographic expression was only 
observed when haloperidol was given in antipsychotic-naïve animals. This result may 
depend on molecular adaptations following prolonged treatments, leading to a more 
homogeneous Homer1a expression and neuronal activation throughout brain regions.  
Amisulpride prominently induced Homer1 expression in the medial caudate-putamen 
when the compound was given in animals previously treated with haloperidol. The 
preferential activation of medial striatal regions had been reported in our previous study 
(de Bartolomeis et al., 2013) and is consistent with the supposed limbic selectivity of 
the compound (Moller et al., 2003), which has been accounted for its claimed 
superiority against negative symptoms (Nuss et al., 2010).  
In conclusion, the results of this study add further insight to the hypothesis that the 
molecular actions exerted by antipsychotics are substantially different according to the 
order in which they are administered (i.e. antipsychotic administration in antipsychotic-
naïve animals vs. previously antipsychotic-treated ones), confirming, at molecular level, 
what it had been observed in neuroimaging studies and in clinical practice. 
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